BMS gets FDA Breakthrough Therapy Designation for investigational HIV treatment

WASHINGTON - July 23, 2015 - PRLog -- The U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to Bristol-Myers Squibb’s investigational compound BMS-663068 when used in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in treatment-experienced adult patients. BMS-663068 is a first-in-class HIV-1 attachment inhibitor and functions differently than other entry inhibitors, the compound works earlier in the replication process by preventing the virus’ initial interaction with immune cells therefore, blocking the virus’ entry into the healthy cell.

The Phase IIb clinical study compared BMS-663068 to a protease inhibitor (Reyataz® (atazanavir sulfate) and ritonavir) in treatment-experienced adult patients, with a treatment backbone across all arms of raltegravir, in addition to tenofovir disoproxil fumarate. At week 48, results from the study were presented at the 22nd Conference on Retroviruses and Opportunistic Infections (CROI) encouraging continued clinical development of the attachment inhibitor.

“We are now 30-plus years into the AIDS epidemic, and there is an ever-increasing number of long-term survivors of the condition, many of whom are facing issues of drug resistance and are in need of new treatment options,” said Douglas Manion, M.D., Head of Specialty Development, Bristol-Myers Squibb. “The Breakthrough Designation recognizes the unmet need for novel therapies for this growing group of heavily treatment-experienced patients, and is evidence of Bristol-Myers Squibb’s continued focus on meeting that need.”

Candidates who want to break into pharmaceutical sales:

Now is the time to enter this wonderful career field! With such industry leaders paving the way on identifying new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained and have the background to promote their product both proficiently and efficiently.

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at

Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share